文献速递血栓与止血

调节纤维蛋白形成速率和凝块结构减轻系统性炎症中的微血管血栓

Modulating the rate of fibrin formation and clot structure attenuates microvascular thrombosis in systemic inflammation.
PubMed 文献 · Blood Adv · 2020-01-01

本研究探讨VWF A2蛋白减轻DIC的机制。A2蛋白通过结合纤维蛋白、增加聚合速率并改变凝块结构,在脂多糖诱导的DIC小鼠中改善生存、减少纤维蛋白沉积和微血管血栓,且不影响实验性血栓形成。

要点

  • A2蛋白通过靶向纤维蛋白形成减轻系统性炎症诱导的DIC
  • A2蛋白不增加出血风险
  • A2蛋白不影响实验性血栓形成

核心结论

  • A2蛋白通过靶向纤维蛋白形成减轻系统性炎症诱导的凝血病/DIC,且不增加出血风险。

研究设计与样本

  • 使用健康人和内毒素血症小鼠血浆进行共聚焦显微镜分析纤维蛋白凝块结构,浊度试验检测纤维蛋白聚合,并采用LPS诱导DIC小鼠模型。

主要发现

  • A2蛋白增加纤维蛋白聚合的初始变化速率,嵌入纤维蛋白网络并改变体外凝块结构。
  • 内毒素血症小鼠血浆离体实验显示A2蛋白增加纤维蛋白形成速率并改变凝块结构。
  • A2蛋白改善内毒素血症诱导DIC小鼠的生存,减少纤维蛋白沉积和微血管血栓,而A2突变体无此效果。
  • 体内外研究表明A2蛋白不影响实验性血栓形成。

临床怎么用

  • A2蛋白可能作为减轻系统性炎症诱导的凝血病/DIC的新型治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Systemic inflammation can lead to coagulopathy and disseminated intravascular coagulation (DIC). In prior studies, the recombinant A2 domain of human von Willebrand factor (VWF; A2 protein) attenuated DIC and decreased mortality in lipopolysaccharide (LPS)-treated mice. Here, we performed studies to dissect the mechanism by which the A2 protein moderates DIC. We used confocal microscopy to analyze the fibrin clot structure in plasma from healthy humans and endotoxemic mice, turbidity assays to examine fibrin polymerization, and a murine model for LPS-induced DIC and introduced a loss-of-function mutation into the A2 protein for fibrin. The mutation of the residue E1567 located in the α2 helix of the folded A2 domain of VWF inhibited binding activity for fibrin, possibly mapping a novel region containing a putative binding site for fibrin. The A2 protein increased the initial rate of change of fibrin polymerization, intercalated into the fibrin network, and modified the resultant clot structure in vitro. Furthermore, ex vivo experiments using plasma from mice with endotoxemia treated with the A2 protein revealed an increased rate of fibrin formation and an altered clot structure as compared with plasma from nontreated sick animals. Moreover, and in contrast to the A2 mutant, the A2 protein improved survival and reduced fibrin deposition and microvascular thrombosis in mice with endotoxemia-induced DIC. Importantly, in vivo and in vitro studies indicated that the A2 protein did not affect experimental thrombosis. Thus, we provide evidence for a novel treatment to attenuate systemic inflammation-induced coagulopathy/DIC via targeting fibrin formation, without an increased risk for bleeding.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Valladolid C, Martinez-Vargas M, Sekhar N, et al. Modulating the rate of fibrin formation and clot structure attenuates microvascular thrombosis in systemic inflammation. Blood Adv. 2020. PMID: 32259201. doi:10.1182/bloodadvances.2020001500

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。